乳腺内分泌外科スタッフの主な業績
Jpn J Clin Oncol in press
Breast Cancer in press
High-Accuracy Prediction of Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma using Focal Cortical Thickening on Magnetic Resonance Imaging
Shun Kawaguchia*, Keiichi Kinowakib, Nobuko Tamuraa, Tomohiko Masumotoc, Aya Nishikawaa, Akio Shibataa, Kiyo Tanakaa, Yoko Kobayashia, Takuya Oguraa, Junichiro Satob and Hidetaka Kawabataa
Front Oncol 2022: 12: 989650
Cells. 2022 Nov 15;11(22):3610.
Sci Rep. 2022 Jun 9;12(1):9495. doi: 10.1038/s41598-022-13601-7.
Pathol Int. 2022 Feb;72(2):96-106. doi: 10.1111/pin.13190. Epub 2021 Dec 8.
TRIM39 is a poor prognostic factor for patients with estrogen receptor-positive breast cancer and promotes cell cycle progression.
Eur J Cancer. 2022 Aug;171:193-202.
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
Int J Mol Sci. 2021, 22, 11505. https://doi.org/10.3390/ijms222111505
OCT1 is a poor prognostic factor for breast cancer patients and promotes cell proliferation via inducing NCAPH
Takuya Ogura, Kotaro Azuma, Junichiro Sato, Keiichi Kinowaki, Ken-Ichi Takayama, Toshihiko Takeiwa, Hidetaka Kawabata, Satoshi Inoue
Breast Cancer Res Treat. 2021 Dec;190(3):425-434.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda N.
Breast Cancer Res Treat. 2021 Jul;188(1):117-131
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
Norikazu Masuda, Hiroko Bando, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori E. Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R. Kataoka, Ryuji Uozumi, Shinji Ohno & Masakazu Toi
Pathol Int 2021 Jan;71(1):60-69
Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population
Junichiro Sato, Kotaro Azuma, Keiichi Kinowaki, Kazuhiro Ikeda, Takuya Ogura, Yutaka Takazawa , Hidetaka Kawabata, Masanobu Kitagawa, Satoshi Inoue
Clin Breast Cancer. 2021 Oct;21(5):399-407
Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer
Junichiro Sato, Kotaro Azuma Keiichi Kinowaki, Kazuhiro Ikeda, Takuya Ogura, YutakaTakazawa, Hidetaka Kawabata, Masanobu Kitagawa, Satoshi Inoue
Breast Cancer. 2021 Jul;28(4):896-903
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Cancer Res. 2020 Jun 1;80(11):2230-2242.
PSF promotes ER-positive breast cancer progression via posttranscriptional regulation of ESR1 and SCFD2
Yuichi Mitobe, Kaori Iino, Ken-ichi Takayama, Kazuhiro Ikeda, Takashi Suzuki, Kenjiro Aogi, Hidetaka Kawabata, Yutaka Suzuki, Kuniko Horie-Inoue and Satoshi Inoue
BMC Cancer 2020 Apr 16;20(1):325. doi: 10.1186/s12885-020-06834-0.
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients
Yuko Tanabe; Seiji Shiraishi; Kenji Hashimoto; Kazutaka Ikeda; Daisuke Nishizawa; Junko Hasegawa; Akihiko Shimomura; Yukinori Ozaki; Nobuko Tamura; Mayu Yunokawa; Kan Yonemori; Toshimi Takano; Hidetaka Kawabata; Kenji Tamura; Yasuhiro Fujiwara; Chikako Shimizu
Cancer Sci. 2019 Nov 16. doi: 10.1111/cas.14240. [Epub ahead of print]
RNA-binding protein NONO promotes breast cancer proliferation via posttranscriptional regulation of SKP2 and E2F8
Iino, Kaori; Mitobe, Yuichi; Ikeda, Kazuhiro; Takayama, Kenichi; Suzuki, Takashi; Kawabata, Hidetaka; Suzuki, Yutaka; Horie-Inoue, Kuniko; Inoue, Satoshi
Mol Cell Biol. 2019 Nov 12;39(23). pii: e00261-19. doi: 10.1128/MCB.00261-19. Print 2019 Dec 1.
ESR1-stabilizing lncRNA TMPO-AS1 promotes hormone-refractory breast cancer progression.
Yuichi Mitobea , Kazuhiro Ikeda , Takashi Suzuki , Kiyoshi Takagi , Hidetaka Kawabata , Kuniko Horie-Inoue and Satoshi Inoue
BMC Cancer. 2019 Oct 22;19(1):980.
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi & Toshimi Takano
Breast. 2018 Apr 23;40:67-75
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.
Asia Pac J Clin Oncol. 2018 Mar 1. doi: 10.1111/ajco.12863
A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y, Uchida Y, Shirakawa K, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Sugiura R, Kawabata H, Seto Y, Ogawa T.
Breast Cancer. 2018 May;25(3):343-349
Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T.
Int J Mol Sci. 2017 Sep 8;18(9). pii: E1931.
Hidetaka Kawabata, Kotaro Azuma, Kazuhiro Ikeda, Ikuko Sugitani, Keiichi Kinowaki, Takeshi Fujii, Akihiko Osaki, Toshiaki Saeki, Kuniko Horie-Inoue, Satoshi Inoue
TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-κB signaling
Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186
Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y.
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Breast Cancer Res Treat. 2014 May;145(1):143-53
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
The Breast 2014 August 23(4) 466-72
Maki Tanioka, Masaoki Sasaki, Akihiko Shimomura, Makoto Fujishima, Mihoko Doi, Kazuo Matsuura, Toshiko Sakuma, Kenichi Yoshimura, Toshiaki Saeki, Masahiro Ohara, Junji Tsurutani,Masahiro Watatani, Toshimi Takano, Hidetaka Kawabata, Hirofumi Mukai, Yoichi Naito, Koichi Hirokaga, Shintaro Takao and Hironobu Minami
Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status
Chemotherapy 2013; 59(2):93-98
Marie Hanaoka, Hidetaka Kawabata, Tsuguo Iwatani, Toshimi Takano, Daishu Miura Reduction of Toxicity by Reversing the Order of Infusion of Docetaxel and Cyclophosphamide.
J Cancer 2013 4:519-523
Miura Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, and Takano T:
The safety of chemotherapy for breast cancer patients with hepatitis C virus infection.
Psycho-Oncology 2012 (Article first published online:DOI: 10.1002/pon.3023)
Tsuguo Iwatani, Ayako Matsuda, Hidetaka Kawabata, Daishu Miura, Eisuke Matsushima
Predictive factors for psychological distress related to diagnosis of breast cancer.
J.Clin.Oncol 2011,29, e113-115
Tsuguo Iwatani, Hidetaka Kawabata, Daishu Miura, Yasunori Ota, Kenichi Ohashi
Complete Spontaneous Regression of Primary Diffuse Large B-cell Lymphoma of the Breast
N Engl J Med 2011;365:1056-7
Marie Hanaoka, Toshimi Takano, Hidetaka Kawabata (Comment on: N Engl J Med 2011; 364: 2381-2391)
Exemestane for Breast-Cancer Prevention.
Breast Cancer, 2009, DOI 10.1007/s12282-009-0149-1
Tsuguo Iwatani, Hidetaka Kawabata, Daishu Miura, Naoko Inoshita, Yasunori Ohta
Nodular fasciitis of the breast.
Lancet,2001,358,1018
Hidetaka Kawabata, Takafumi Ueno
Screening recommendation for women taking tamoxifen
Lancet 2000,355,238
Takafumi Ueno、Hidetaka Kawabata
Tobacco and health care professionals in Japan
Lancet 1999,354,1207
Hidetaka Kawabata，Takafumi Ueno
Early Lung Cancer Action Project.
Lancet 1999,353,2077
Hidetaka Kawabata，Takafumi Ueno
Controversy over cancer chemotherapy in Japan
冲中記念成人病研究所・研究員 川端英孝
川端英孝（かわばた ひでたか）
（キャリア） 1988年東京大学医学部卒業後、同大学第二外科学教室にて外科の基本を学び（出月康夫教授、幕内雅敏教授）、専門分野として乳腺内分泌外科グループに所属しました。同大学第二外科助手 JR東京総合病院外科医長などを経て2006年9月から虎の門病院乳腺内分泌外科部長として赴任し現在に至っています。また埼玉医科大学国際医療センターにて学位を取得（指導教官：佐伯俊昭乳腺腫瘍科教授・現病院長）し、現在も埼玉医科大学非常勤講師を兼任しております。日本乳癌学会では乳腺専門医・指導医・評議員、研究倫理審査小委員会委員長、倫理委員会委員、認定委員会委員・関東地区委員長などの役にあり、2019年日本乳癌学会総会プログラム委員長を務めました。
（研究分野） 研究分野では学位取得でお世話になった東京都健康長寿医療センター研究所・井上聡研究部長（埼玉医科大学ゲノム医学研究センター部門長兼任）の元で、ホルモン依存性がんにおけるゲノム・エピゲノム・非ゲノム作用解析に関わらせていただいており、その中で虎の門病院の臨床検体ならびに冲中記念成人病研究所の施設を活用させていただいております。
（今後の抱負とアピール） 私自身は臨床医としてこれまで多くの患者さんの治療に関わり、多くの経験をさせていただきました。今後は基礎研究者と協力しながら臨床検体を用いた研究を通じて世の中のお役に立てればと考えています。またこうした活動が虎の門病院に所属する若い医師たちの今後のキャリアデベロップメントの一助になることも同時に願っています。
論文業績（2017年以降）
Cancer Res (in press)
PSF promotes ER-positive breast cancer progression via posttranscriptional regulation of ESR1 and SCFD2
Yuichi Mitobe, Kaori Iino, Ken-ichi Takayama, Kazuhiro Ikeda, Takashi Suzuki, Kenjiro Aogi, Hidetaka Kawabata, Yutaka Suzuki, Kuniko Horie-Inoue and Satoshi Inoue
Cancer Sci. 2019 Nov 16. doi: 10.1111/cas.14240. [Epub ahead of print]
RNA-binding protein NONO promotes breast cancer proliferation via posttranscriptional regulation of SKP2 and E2F8
Iino, Kaori; Mitobe, Yuichi; Ikeda, Kazuhiro; Takayama, Kenichi; Suzuki, Takashi; Kawabata, Hidetaka; Suzuki, Yutaka; Horie-Inoue, Kuniko; Inoue, Satoshi
Mol Cell Biol. 2019 Nov 12;39(23). pii: e00261-19. doi: 10.1128/MCB.00261-19. Print 2019 Dec
ESR1-stabilizing lncRNA TMPO-AS1 promotes hormone-refractory breast cancer progression.
Yuichi Mitobea , Kazuhiro Ikeda , Takashi Suzuki , Kiyoshi Takagi , Hidetaka Kawabata , Kuniko Horie-Inoue and Satoshi Inoue
BMC Cancer. 2019 Oct 22;19(1):980. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi & Toshimi Takano
Breast. 2018 Apr 23;40:67-75 A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.
Asia Pac J Clin Oncol. 2018 Mar 1. doi: 10.1111/ajco.12863 A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y, Uchida Y, Shirakawa K, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Sugiura R, Kawabata H, Seto Y, Ogawa T.
Breast Cancer. 2018 May;25(3):343-349 Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T.
Int J Mol Sci. 2017 Sep 8;18(9). pii: E1931.
TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-κB signaling
Hidetaka Kawabata, Kotaro Azuma, Kazuhiro Ikeda, Ikuko Sugitani, Keiichi Kinowaki, Takeshi Fujii, Akihiko Osaki, Toshiaki Saeki, Kuniko Horie-Inoue, Satoshi Inoue
Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186
Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y.
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.